PASG News and Press, Passage Bio Inc. From 03/03/22

Passage Bio press release (NASDAQ:PASG): Q4 GAAP EPS of -$0.95 misses by $0.06. Q4 cash equivalents $315.8M For further details see: Passage Bio GAAP EPS of -$0.95 misses by $0.06

Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestones, for Cohort 1 patients in Imagine-1 clinical trial for GM1 gangliosidosis Dosed first patients in Cohorts 2 (late infantile, high dose) and 3 (early infantile, low dose) i...

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m....

The following slide deck was published by Passage Bio, Inc. in conjunction with this event. For further details see: Passage Bio (PASG) Presents At 2022 WORLD Symposium Data Conference

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregivers Interim safety data at three and nine months in Imagine-1 showed low dose PBGM01 well tolerated with...

The following slide deck was published by Passage Bio, Inc. in conjunction with this event. For further details see: Passage Bio (PASG) Presents At J.P. Morgan 40th Annual Healthcare Conference

Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11 Podium presentations on clinical trial designs for Imagine-1 and GALax-C, the clinical trial for Krabbe disease, Wednesday, February 9 G...

Present longer follow-up and clinical milestones for Cohort 1 of the Imagine-1 GM1 gangliosidosis clinical trial at the 18 th Annual WORLD Symposium, February 11, 2022 Dose first patients in Cohorts 2 and 3 in GM1 gangliosidosis clinical trial in early 2022 ...

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Bruce Goldsmith, Ph.D., president, and chief executive...

– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious adverse events, no complications related to intra-cisterna magna inj...